XOMA Co. (NASDAQ:XOMA) CEO Owen Hughes Sells 21,881 Shares

XOMA Co. (NASDAQ:XOMA) CEO Owen Hughes sold 21,881 shares of XOMA stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $29.95, for a total transaction of $655,335.95. Following the completion of the sale, the chief executive officer now owns 34,979 shares of the company’s stock, valued at $1,047,621.05. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

XOMA Stock Down 5.0 %

Shares of XOMA traded down $1.55 during midday trading on Wednesday, reaching $29.71. 116,262 shares of the stock were exchanged, compared to its average volume of 21,623. The firm has a 50 day simple moving average of $28.60 and a 200-day simple moving average of $26.84. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28. XOMA Co. has a 12-month low of $14.33 and a 12-month high of $33.78. The company has a market cap of $349.98 million, a price-to-earnings ratio of -8.54 and a beta of 0.90.

XOMA (NASDAQ:XOMA) last released its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. The firm had revenue of $11.09 million for the quarter, compared to the consensus estimate of $8.37 million. Research analysts forecast that XOMA Co. will post -0.79 EPS for the current year.

Wall Street Analysts Forecast Growth

XOMA has been the topic of several recent research reports. StockNews.com raised shares of XOMA from a “sell” rating to a “hold” rating in a research report on Wednesday, August 14th. HC Wainwright reaffirmed a “buy” rating and set a $117.00 price target on shares of XOMA in a report on Wednesday, October 23rd.

Institutional Trading of XOMA

Institutional investors and hedge funds have recently bought and sold shares of the business. BNP Paribas Financial Markets grew its stake in shares of XOMA by 95.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 795 shares during the period. Price T Rowe Associates Inc. MD purchased a new position in shares of XOMA during the 1st quarter valued at $212,000. Rhumbline Advisers increased its stake in XOMA by 16.0% in the second quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock valued at $230,000 after acquiring an additional 1,334 shares during the last quarter. Ellsworth Advisors LLC bought a new position in XOMA in the third quarter valued at $516,000. Finally, Bank of New York Mellon Corp grew its stake in shares of XOMA by 3.2% during the second quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock valued at $1,484,000 after buying an additional 1,968 shares during the last quarter. Institutional investors own 95.92% of the company’s stock.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.